EU Accelerated Assessment Tracker
At least another four investigational therapies will join the few that are already being fast-tracked at the European Medicines Agency.
You may also be interested in...
Review Of BMS's CAR-T Therapy Liso-Cel Gets Under Way At EMA
Bristol Myers Squibb's lisocabtagene maraleucel, UCB's bimekizumab and Rhythm Pharmaceuticals' setmelanotide are among the six latest additions to the list of products under review at the European Medicines Agency.
Bluebird Seeks EU Fast-Track Review For Lenti-D Gene Therapy
Bluebird bio is planning to file its EU marketing application for Lenti-D this year, before it files for approval in the US in mid-2021.
Latest EU Filings Include A First For BeiGene
Potential treatments from BeiGene, AstraZeneca, Bayer and Cancer Prevention Pharmaceuticals are under review at the European Medicines Agency.